Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial

Abstract

Twice-weekly paclitaxel with concurrent RT is a feasible and effective primary treatment for LABC. Future studies should compare primary chemoradiation to chemotherapy in LABC.

Neoadjuvant Radiotherapy of Early-Stage and Locally Advanced Breast Cancer: Review of the Literature

“…Brackstone et al [8] in this first clinical trial evaluating concurrent neoadjuvant CCRT with a taxane as part of a modern chemotherapy regimen (FEC-D), support the same findings of the Formenti group. He suggests that this regimen significantly improved the PCR rate in LABC patients; however, the benefit shown in DFS and OS at 3 years was not statistically significant when compared with a propensity-matched control group.…”

“…In the other hand Formenti et al [8] has concluded that toxicities can be considerably reduced if paclitaxel is administered twice weekly at 30 mg/m 2 as an alternative of weekly at 80 mg/m 2 or as a continuous infusion at 20-30 mg/m 2 daily. Moreover, update data demonstrated that pathological response was higher and was associated with better disease-free survival (DFS) and overall survival OS when compared with non-responders within the same treatment cohort [8].…”

“…Moreover, update data demonstrated that pathological response was higher and was associated with better disease-free survival (DFS) and overall survival OS when compared with non-responders within the same treatment cohort [8].…”

“…In exploring the role of CCRT in breast cancer, PCR was higher and was associated with better disease-free survival (DFS) and overall survival (OS). However, it seems to be associated with a high rate of toxicities with certain chemotherapy regimens and schedule [8][9][10][11][12][13][14]. On the other hand, CCRT limits the duration of treatment and the required hospital visits, without compromising quality of life [15].…”

Long-term results of combined and complex treatment of patients with locally advanced HER2-positive breast cancer

“…С другой стороны -может при-вести к развитию серьезных осложнений. В литературе к настоящему моменту представлены данные различных исследований по безопасности и эффективности как па-раллельного [4,5,6,7], так и последовательного приме-нения химиолучевой терапии [8,9,10]. Помимо этого, активно изучается радиочувствительность опухолей, обладающих гиперэкспрессией HER2 / neu [11].…”